HPV Gardasil Vaccine Should be Recalled

by | Mar 3, 2010


From June 2006 to January 31, 2010, there have been 15,829 reports of adverse events, including 49 deaths, from 28 million doses of Merk’s Gardasil Human Papillomavirus (HPV) vaccine administered in the United States to girls ages 9 to 26. (see CDC: Reports of Health Concerns Following HPV Vaccination)

A green chalkboard with the message 'I LOVE YOU' written in white chalk.

The adverse events reports following Gardasil vaccinations have included fainting, pain, and swelling at the injection site (the arm), headache, nausea, fever, neurological disorders, paralysis, Guillain-Barré Syndrome (GBS) and 49 deaths in the United States.


Although the cause of the adverse events is not known, the HPV Vaccine contains 225mcg of Aluminum, a known neurotoxin, and 50mcg of Polysorbate 80, which has been shown to cause severe anaphylactic reactions, in every vaccine dose.


Why shouldn’t Merck Pharmaceutics, the manufacturer of the Garasil vaccine, be forced to recall this vaccine? It should be taken off of the market until it can be fixed and proven safe.


Toyota’s Adverse Event numbers pale in comparison to those of Merck. According to the U.S. National Highway Traffic Safety Administration, no more than a few thousand complaints have been filed against Toyota vehicles possibly linked to unintended acceleration, which have caused 43 fatal crashes with 52 deaths and 38 injuries in a ten year period from 2000 to 2010.

Merck advertising campaign deceptive – pressuring – scary

A green chalkboard with the message 'I LOVE YOU' written in white chalk.

Moms and their young daughters are feeling pressured into getting the Gardasil vaccine. Young girls get the message that it’s the hip – adult thing to do and that they are somehow a heroine if they get the vaccine.

Moms get the message that they are being irresponsible if they don’t get their daughters vaccinated before they hit puberty. They both are deceived into believing that the Gardasil vaccine is completely free of side-effects and totally prevents cervical cancer.


The truth is the Gardasil vaccine does not prevent cancer at all. It is licensed only to prevent 2 of the 30 sexually transmitted types of HPV virus that may cause cervical cancer.


The massive advertising campaign for Gardasil by Merck claims that it is “the only vaccine that may help protect you from the four types of Human Papilloma virus that may cause 70% of cervical cancer.â€


Research published in the Journal of the American Medical Association (JAMA, Feb 28, 2007), revealed that only 3.4% of young girls and women that get HPV are infected with one of the four HPV types that are included in the Gardasil vaccine.


The CDC reports that approximately 6.2 million women are diagnosed with HPV every year and 11,500 get invasive cervical cancer and 3500 die. Although that is too many deaths, 11,500 cases of cervical cancer out of 6.2 million cases of HPV means that only 0.2% of women go on to develop cervical cancer from HPV. That means that 99.8% of women with HPV do not get cervical cancer.


Research published in the Journal of the American Medical Association (JAMA, Feb 28, 2007), revealed that only 3.4% of young girls and women that get HPV are infected with one of the four HPV types that are included in the Gardasil vaccine.


The CDC reports that approximately 6.2 million women are diagnosed with HPV every year and 11,500 get invasive cervical cancer and 3500 die. Although that is too many deaths, 11,500 cases of cervical cancer out of 6.2 million cases of HPV means that only 0.2% of women go on to develop cervical cancer from HPV. That means that 99.8% of women with HPV do not get cervical cancer.


Research published in the Journal of the American Medical Association (JAMA, Feb 28, 2007), revealed that only 3.4% of young girls and women that get HPV are infected with one of the four HPV types that are included in the Gardasil vaccine.


The CDC reports that approximately 6.2 million women are diagnosed with HPV every year and 11,500 get invasive cervical cancer and 3500 die. Although that is too many deaths, 11,500 cases of cervical cancer out of 6.2 million cases of HPV means that only 0.2% of women go on to develop cervical cancer from HPV. That means that 99.8% of women with HPV do not get cervical cancer.


The truth is as the CDC’s website also states, “HPV usually goes away on its own, without causing health problems. So an HPV infection that is found today will most likely not be there a year or two from now.â€


“About 70% of HPV infections appear to go away within a year and 90% within 2 years. â€


“In 90% of cases, the body’s immune system clears the HPV infection within 2 years. This is true of both high-risk and low-risk HPV types.â€

So why does anyone need this vaccine? Is it worth the risks?

To learn about the natural non-vaccine approach to prevention and treatment of HPV and Abnormal Pap Smears, click here.

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Receive Our Newsletter

11 + 1 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });